R01NS127865
Project Grant
Overview
Grant Description
Trauma, the gut, and the brain: the gut microbiota-microglia axis in traumatic brain injury - project summary/abstract
Trauma is the leading cause of death and disability in young adults in the United States. Traumatic brain injury (TBI) contributes to over one third of all these trauma-related deaths. In fact, TBI-related healthcare expenditures near 80 billion dollars annually. The impact of TBI is highlighted not only by its high mortality rate, but also the significant long-term cognitive and psychiatric complications suffered by its survivors.
Chronic neuroinflammation resulting from the constitutive activation of microglia is complicit in this process and represents a complex interplay between microglia and the gut microbiome via the gut-brain axis. However, the mechanism(s) underlying gut microbiota-microglia interaction have yet to be elucidated.
Published data from our laboratory shows a significantly altered gut microbial community after TBI, with increased relative abundance of several microbial species strongly associated with neurologic disease processes. In the same vein, it is known that reduced abundance of anaerobic bacteria capable of fermenting dietary fiber into short chain fatty acids (SCFAs) exacerbate lesion size and neuroinflammation after neurologic injury.
Preliminary data from our laboratory has shown improved neurocognitive outcomes with dietary supplementation of the SCFAs acetate, butyrate, and propionate after TBI. Nonetheless, the mechanism(s) linking TBI-induced alterations in the gut microbial community to the development of subsequent neurocognitive decline have yet to be fully elucidated.
We hypothesize that targeted microbial and dietary intervention will attenuate microglial activation and neurocognitive outcomes after TBI. To test this hypothesis, we will determine whether restoring a pre-injury gut microbial composition via fecal microbiota transplant, targeted microbiota replacement, or dietary supplementation of SCFAs attenuates the activation of microglia in wild type, germ-free, and genetic targeted replacement mice.
We will use bulk population cell sorting (FACS sorting) of microglia followed by single cell RNA sequencing (scRNA-seq). We will compare candidate genes to microbial activity via fecal 16S rRNA gene amplicon sequencing and fecal metabolite analysis.
Harmonized with the transcriptomic and gut microbial community profiling, all aims will utilize longitudinal PET/CT imaging of the 18-kDa translocator protein (TSPO) with a novel fluorine-based radiotracer developed by our group to track and compare the onset, progression, and degree of microglial activation before, during, and after gut microbial and dietary intervention after TBI.
Collectively, the proposed studies will identify the key role of gut microbial community structure and metabolic activity in the onset and progression of constitutive microglial activation over the course of TBI, thus raising the potential for novel therapeutic and biomarker development in TBI patients.
Trauma is the leading cause of death and disability in young adults in the United States. Traumatic brain injury (TBI) contributes to over one third of all these trauma-related deaths. In fact, TBI-related healthcare expenditures near 80 billion dollars annually. The impact of TBI is highlighted not only by its high mortality rate, but also the significant long-term cognitive and psychiatric complications suffered by its survivors.
Chronic neuroinflammation resulting from the constitutive activation of microglia is complicit in this process and represents a complex interplay between microglia and the gut microbiome via the gut-brain axis. However, the mechanism(s) underlying gut microbiota-microglia interaction have yet to be elucidated.
Published data from our laboratory shows a significantly altered gut microbial community after TBI, with increased relative abundance of several microbial species strongly associated with neurologic disease processes. In the same vein, it is known that reduced abundance of anaerobic bacteria capable of fermenting dietary fiber into short chain fatty acids (SCFAs) exacerbate lesion size and neuroinflammation after neurologic injury.
Preliminary data from our laboratory has shown improved neurocognitive outcomes with dietary supplementation of the SCFAs acetate, butyrate, and propionate after TBI. Nonetheless, the mechanism(s) linking TBI-induced alterations in the gut microbial community to the development of subsequent neurocognitive decline have yet to be fully elucidated.
We hypothesize that targeted microbial and dietary intervention will attenuate microglial activation and neurocognitive outcomes after TBI. To test this hypothesis, we will determine whether restoring a pre-injury gut microbial composition via fecal microbiota transplant, targeted microbiota replacement, or dietary supplementation of SCFAs attenuates the activation of microglia in wild type, germ-free, and genetic targeted replacement mice.
We will use bulk population cell sorting (FACS sorting) of microglia followed by single cell RNA sequencing (scRNA-seq). We will compare candidate genes to microbial activity via fecal 16S rRNA gene amplicon sequencing and fecal metabolite analysis.
Harmonized with the transcriptomic and gut microbial community profiling, all aims will utilize longitudinal PET/CT imaging of the 18-kDa translocator protein (TSPO) with a novel fluorine-based radiotracer developed by our group to track and compare the onset, progression, and degree of microglial activation before, during, and after gut microbial and dietary intervention after TBI.
Collectively, the proposed studies will identify the key role of gut microbial community structure and metabolic activity in the onset and progression of constitutive microglial activation over the course of TBI, thus raising the potential for novel therapeutic and biomarker development in TBI patients.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Chicago,
Illinois
606112987
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 386% from $627,033 to $3,049,092.
Northwestern University was awarded
Gut Microbiota Intervention Microglial Activation in Traumatic Brain Injury
Project Grant R01NS127865
worth $3,049,092
from the National Institute of Neurological Disorders and Stroke in August 2022 with work to be completed primarily in Chicago Illinois United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders.
The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 7/20/26
Period of Performance
8/1/22
Start Date
7/31/27
End Date
Funding Split
$3.0M
Federal Obligation
$0.0
Non-Federal Obligation
$3.0M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for R01NS127865
Transaction History
Modifications to R01NS127865
Additional Detail
Award ID FAIN
R01NS127865
SAI Number
R01NS127865-133956963
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NQ00 NIH National Institute of Neurological Disorders and Stroke
Funding Office
75NQ00 NIH National Institute of Neurological Disorders and Stroke
Awardee UEI
KG76WYENL5K1
Awardee CAGE
01725
Performance District
IL-05
Senators
Richard Durbin
Tammy Duckworth
Tammy Duckworth
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute of Neurological Disorders and Stroke, National Institutes of Health, Health and Human Services (075-0886) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,237,124 | 100% |
Modified: 7/20/26